deferiprone has been researched along with Bright Disease in 1 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajapurkar, MM | 1 |
| Hegde, U | 1 |
| Bhattacharya, A | 1 |
| Alam, MG | 1 |
| Shah, SV | 1 |
1 trial available for deferiprone and Bright Disease
| Article | Year |
|---|---|
Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferiprone; Diabetic Nephropathies; Drug Therapy, Combi | 2013 |